Secondary outcomes
hypoglycaemia
REGRESSION, SECONDARY, SIDE EFFECT, HYPOGLYCAEMIA
There was no difference in tolerability between BMI strata for pioglitazone, compared with sitagliptin (odds ratio (OR) (95% CI) 2.11 (0.66, 6.76) for drug*BMI strata interaction in a mixed effects logistic regression analysis (p=0.2; There was no difference in the odds of experiencing at least one side effect for either of the drug/strata combinations of interest (OR (95%CI) 0.68 (0.31, 1.45), p=0.3 for drug*BMI strata interaction; OR (95%CI) 1.46 (0.70, 3.04), p=0.3 for drug*eGFR strata interaction) (There was evidence of period and carryover effects for weight, with participants being heavier on average as the trial progressed and with a carryover effect (p<0.001) with either canagliflozin or sitagliptin treatment in the previous period associated with lower weight, compared with pioglitazone treatment in the previous period (There was no evidence of any difference in the odds of experiencing hypoglycaemia by BMI strata for pioglitazone and sitagliptin, or by eGFR strata for sitagliptin and canagliflozin (Participant drug preference was a prespecified secondary analysis and is reported in a separate publication